Tratamiento de hepatitis C con antivirales pangenotípicos de acción directa: Interacciones farmacológicas en pacientes que consumen drogas y tratados con antipsicóticos
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
People who use drugs (PWUD) are at high risk of hepatitis C virus (HCV) infection, and HCV patients often have psychiatric disorders requiring nervous system drugs, including antipsychotics. These medicines can interact with HCV treatment-related metabolic pathways producing DDIs (drug-drug interactions). This analysis focused on potential DDIs between direct-acting antivirals (DAAs) and concomitant medications used in PWUD/antipsychotics-treated HCV patients, alongside associated adverse events (AEs) and clinical interventions in Spain. Electronic medical records (BIG-PAC® database) were used to analyse adult HCV patients treated with glecaprevir/pibrentasvir (GLE/PIB) or sofosbuvir/velpatasvir (SOF/VEL) between 2017-2020. The study included 1,620 HCV patients, 985 identified as PWUD and 187 as antipsychotic users, 75% of whom were also PWUD. In the PWUD cohort, cardiovascular (CV) comorbidities were the most frequent; 22.7% patients were at risk of DDIs with CV, with the risk being higher in GLE/PIB-treated (36.8%) versus SOF/VEL (13.7%) (p
Fields of Study & Subjects
Hepatitis C virus research
Pharmacogenetics and Drug Metabolism
HIV
Drug Use
Sexual Risk
Publication details
- Journal / source
- Adicciones
- Volume
- 38
- Issue
- 1
- Pages
- 25–40
- Publication date
- 31 March 2026
- Language
- ES